Surmodics Acquires Alta Biomed to Expand Device Capabilities

Surmodics has acquired the business of Alta Biomed, according to Pulse2. Pulse2 reports that the transaction expands Surmodics’ portfolio of hemocompatible and biocompatible surface technologies and adds specialized testing capabilities for blood- and tissue-contacting medical devices.

Transaction expands surface technology portfolio

Pulse2 characterizes the acquisition as an expansion of Surmodics’ medical-device coating and testing capabilities. The reported additions include hemocompatible and biocompatible surface technologies, areas relevant to devices that contact blood or tissue.

Alta Biomed’s specialized testing capabilities are also part of the acquired business, Pulse2 reports. The announcement connects surface technologies with testing capabilities for blood- and tissue-contacting medical devices.

Focus on blood- and tissue-contacting devices

According to Pulse2, the capabilities added through the acquisition are specialized for medical devices that contact blood and tissue. That focus places the announcement within medical-device applications where hemocompatibility, biocompatibility, and specialized testing are part of the reported portfolio expansion.

For medical-device sales professionals, the news provides a defined portfolio update to track in conversations involving surface technologies and testing capabilities. Pulse2’s report identifies both as components of Surmodics’ expanded offering following the acquisition of Alta Biomed’s business.

Commercial relevance

Sales teams serving medical-device customers can note the reported combination of surface technology and testing capabilities. The acquisition is relevant to discussions concerning blood- and tissue-contacting devices because Pulse2 specifically identifies those device categories in describing the specialized testing capabilities added to Surmodics’ portfolio.

The transaction also gives commercial professionals a reason to review how Surmodics describes its hemocompatible and biocompatible surface technologies alongside the testing capabilities acquired from Alta Biomed. According to Pulse2, the acquisition is intended to expand Surmodics’ capabilities in these areas.

Key takeaway

Pulse2 reports that Surmodics’ acquisition of Alta Biomed’s business expands its portfolio of hemocompatible and biocompatible surface technologies while adding specialized testing for blood- and tissue-contacting medical devices. For medical-device sales professionals, the event is a portfolio development centered on coatings, surface technologies, and testing capabilities.